News Home

Bristol-Myers Squibb Co (BMY) has fallen -3.33% in a Week, Should You Sell?

Tuesday, January 25, 2022 02:14 PM | InvestorsObserver Analysts
Bristol-Myers Squibb Co (BMY) has fallen -3.33% in a Week, Should You Sell?

Bristol-Myers Squibb Co (BMY) is near the top in its industry group according to InvestorsObserver. BMY gets an overall rating of 59. That means it scores higher than 59 percent of stocks. Bristol-Myers Squibb Co gets a 90 rank in the Drug Manufacturers - General industry. Drug Manufacturers - General is number 74 out of 148 industries.

Overall Score - 59
BMY has an Overall Score of 59. Find out what this means to you and get the rest of the rankings on BMY!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Bristol-Myers Squibb Co Stock Today?

Bristol-Myers Squibb Co (BMY) stock has risen 0.21% while the S&P 500 is lower by -0.9% as of 2:13 PM on Tuesday, Jan 25. BMY is higher by $0.13 from the previous closing price of $62.60 on volume of 5,761,736 shares. Over the past year the S&P 500 has risen 13.36% while BMY is lower by -3.24%. BMY lost -$2.40 per share the over the last 12 months. Click Here to get the full Stock Report for Bristol-Myers Squibb Co stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App